Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Six Week Radiographic Comparison of HipGrid® Drone™ and PhantomMSK® Hip

OrthoGrid announces a new clinical whitepaper for review. A retrospective evaluation was conducted for a consecutive cohort of patients having undergone unilateral total hip arthroplasty via the direct anterior approach between January 2017 and January 2020. All procedures were performed at a single site, by a single, fellowship trained orthopedic surgeon. Intraoperative fluoroscopy was supplemented…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Six Week Radiographic Comparison of HipGrid® Drone™ and PhantomMSK® Hip

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

OrthoGrid announces a new clinical whitepaper for review.

A retrospective evaluation was conducted for a consecutive cohort of patients having undergone unilateral total hip arthroplasty via the direct anterior approach between January 2017 and January 2020. All procedures were performed at a single site, by a single, fellowship trained orthopedic surgeon. Intraoperative fluoroscopy was supplemented by either the HipGrid®Drone™ (Drone) or PhantomMSK® Hip (Phantom) (OrthoGrid Systems Inc.

, Salt Lake City, UT, USA) to assist in the positioning of total hip arthroplasty components including cementless, short femoral stem and acetabular cup. The pre-defined target leg length discrepancy (LLD) and global hip offset (GHO) was less than 10mm and acetabular cup abduction angle (ABD) target was 45 degrees plus or minus 10 degrees for the Drone and 42 degrees plus or minus 10 degrees for the Phantom. Accuracy of component placement was evaluated on the six-week post-operative, weight bearing radiographs.

Fluoroscopy times were recorded directly from the c-arm imaging device and surgical times were defined as incision to wound closure. Percentages of patients achieving each component placement goal, as well as reaching all three accuracy goals, were also evaluated. Continuous variables were non-parametric, therefore, group differences were determined by the Mann-Whitney U test and categorical data were evaluated with the Fisher Exact test.

Click here to download the whitepaper:

Some of the data in this whitepaper were previously published in the Journal of Arthroplasty (DOI: 10/1016/j.arth.2020.06.053) by senior surgeon Dr. Cass Nakasone of Straub Medical Center, Bone and Joint Center, Honolulu, HI 96813. Click here to view the article on arthroplastyjournal.org.

To request a HipGrid Drone product demo or a PhantomMSK Hip software demo, please click here.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512